Georgios Trimis - Academia.edu (original) (raw)

Papers by Georgios Trimis

Cancer Medicine, Jan 20, 2024

Value in Health, Nov 30, 2023

Journal of Postgraduate Medicine, Oct 1, 2004

Ataxia-telangiectasia (A-T) is a rare multisystem, neurodegenerative genetic disorder. We present... more Ataxia-telangiectasia (A-T) is a rare multisystem, neurodegenerative genetic disorder. We present a case of a 6-year-old girl who had a history of frequent respiratory infections and also had ocular and immunological features of this syndrome. The absence of neurological symptoms, which is very unusual for a patient of this age, raised many difficulties in the diagnosis of the disease. It is concluded that a normal neurological assessment must not exclude the diagnosis of AT and delay the proper interventional measures.

Clinical Microbiology and Infection, 2003

We present a case of Guillain-Barré syndrome (GBS) following Campylobacter jejuni HS serotype O:1... more We present a case of Guillain-Barré syndrome (GBS) following Campylobacter jejuni HS serotype O:19 infection in a child. Antibodies against C. jejuni and autoantibodies to the peripheral nerve gangliosides GM1 were positive, a pattern correlating well with the existence of an inflammatory neuropathy like GBS. The patient shared the HLA-B35 and HLA-DR8 antigens, which have been found to be increased in GBS patients with previous C. jejuni infection. As this is the first diagnosed C. jejuni-associated GBS case reported from Greece, further clinical and epidemiologic investigations are warranted.

Haemophilia, 2006

The development of antibodies to factor VIII (FVIII) in severely affected haemophilia A patients ... more The development of antibodies to factor VIII (FVIII) in severely affected haemophilia A patients is a serious complication associated with increased morbidity and mortality. Bypassing agents are used to treat acute bleeding episodes; however, elimination of the inhibitors can only be achieved with immune tolerance therapy (ITT) in 60-80% of cases. High responding (HR) inhibitors are more likely to respond to ITT if the titre is decreased to <5 BU over time or in selected cases after the administration of immunosuppressive drugs, plasmapheresis or immunoabsorption, techniques difficult to apply in children. Anti-CD20 (rituximab), a monoclonal antibody, was given as an alternative treatment in two haemophilic children with HR inhibitors and impaired quality of life, due to recurrent haemarthrosis. Rituximab was given at the dose of 375 mg m)2 , once weekly for four consecutive weeks. Both patients showed a partial response to rituximab reducing the inhibitor titre to <5 BU, thus facilitating ITT initiation; however, only the older patient eradicated the inhibitor within 21 days after application of ITT. The second patient, despite depletion of B cells, did not respond to ITT. No long-term side effects have been observed in both patients for a follow-up period of 20 and 18 months respectively. In conclusion, rituximab appears to be an alternative effective therapy to rapidly reduce or eliminate the inhibitor in selected cases of severely affected haemophiliacs before further proceeding to ITT. However, the dose and appropriate schedule, as well as long-term side effects need further investigation.

Blood, Nov 16, 2005

in the field of palliative medicine, the latter having a significant training requirement in pain... more in the field of palliative medicine, the latter having a significant training requirement in pain management. The report of Hewitt et al tells us about a prospective study that looked at the treatment of pain in children with incurable cancer within the Children's Cancer Study Group centers in the United Kingdom. Although the study did not address the efficacy of the opioid regimens used, it did show that the liberal use of high-potency opiates should be an integral part of interdisciplinary palliative care for advanced cancer. Morphine was the opiate most commonly used and it was often administered intravenously at the end of life. It was clear that some patients required unusually high doses of morphine (more than 20 mg/ kg/24 hours). Some youngsters required as much as 1500 mg/kg/24 hours of morphine to control pain. Obviously, there is a delicate balance between achieving adequate pain control and avoiding undesirable side effects. The provision of sedation to a level that allows a child to be unaware of suffering has also been debated, an area that is ethically challenging. All of us recognize that proper pain management is only a single component of palliative care. As we develop more expertise in palliative care, it may well be that simply administering pain medications will prove not to be the only, or necessarily best, way to alleviate pain. The editorial which accompanied this report reminds us that as many as 80% of the quarter of a million children throughout the world who develop cancer each year die without adequate treatment or without adequate pain relief.

Eurosurveillance, Nov 24, 2022

Haemophilia, 2006

Summary. The development of antibodies to factor VIII (FVIII) in severely affected haemophilia A... more Summary. The development of antibodies to factor VIII (FVIII) in severely affected haemophilia A patients is a serious complication associated with increased morbidity and mortality. Bypassing agents are used to treat acute bleeding episodes; however, elimination of the inhibitors can only be achieved with immune tolerance therapy (ITT) in 60–80% of cases. High responding (HR) inhibitors are more likely to respond to ITT if the titre is decreased to <5 BU over time or in selected cases after the administration of immunosuppressive drugs, plasmapheresis or immunoabsorption, techniques difficult to apply in children. Anti‐CD20 (rituximab), a monoclonal antibody, was given as an alternative treatment in two haemophilic children with HR inhibitors and impaired quality of life, due to recurrent haemarthrosis. Rituximab was given at the dose of 375 mg m−2, once weekly for four consecutive weeks. Both patients showed a partial response to rituximab reducing the inhibitor titre to <5...

Journal of Paediatrics and Child Health, 2003

: A 12‐year‐old girl with chronic otitis media complicated by petrositis and cerebellar abscess ... more : A 12‐year‐old girl with chronic otitis media complicated by petrositis and cerebellar abscess is presented. Early surgical intervention, in combination with broad‐spectrum antibiotics, provided a good outcome. Life‐threatening complications of otitis media, although rare, still occur in developed countries.

Purpose: To investigate the presence of early indicators of the dysmetabolic syndrome (DS) in a p... more Purpose: To investigate the presence of early indicators of the dysmetabolic syndrome (DS) in a population of young survivors with acute lymphoblastic leukemia (ALL) in childhood. Patients and Methods: We enrolled randomly 80 patients with ALL (50 males) diagnosed between 1991-2002. The median age at the time of study entry was 13.9 yrs (range, 5.2-24.1) and the median interval since completion of chemotherapy was 6.3 yrs (range, 1.1-12.2). Sixty-two patients (Group A) received chemotherapy only, while 18 patients (Group B) received chemotherapy and cranial irradiation (18 Gy). The investigation included epidemiological, clinical, biochemical, hormonological and imaging data in order to detect early indicators of DS development. Results: An unhealthy diet (74%; CI 95%, 63.1-82.2%) and absence of regular physical activity (64%; CI 95%, 52.8-73.4%) were reported, while frank obesity (25%; CI 95%, 16.7-35.6%), increased blood pressure (21%; CI 95%, 13.6-31.5%), increased serum triglyce...

Blood, 2009

4112 New treatment protocols have improved significantly the survival of patients with acute lymp... more 4112 New treatment protocols have improved significantly the survival of patients with acute lymphocytic leukemia (ALL). However, there is a risk of relapse, which depends on disease classification and the protocol of chemotherapy administered. In case of relapse, new remission has to be achieved to proceed to bone marrow transplantation (BMT). For this reason, new therapies for remission induction, except standard chemotherapy, are under investigation. Clofarabine, a new class agent, is a nucleoside analogue of purine which inhibits DNA synthesis and repair by blocking ribonucleoside reductase and DNA polymerase. It also disrupts mitochondrial membrane, driving to cell apoptosis. We describe two children with B-cell ALL, in whom clofarabine was administered because of disease resistance. Case 1: Girl, 12 years old, with ALL, presented a second bone marrow (BM) relapse. The first relapse was also in BM and was presented 30 months after the end of primary chemotherapy. Remission was ...

Background: Combined immunodeficiency disorders comprise a heterogeneous group of diseases charac... more Background: Combined immunodeficiency disorders comprise a heterogeneous group of diseases characterized by both humoral and cell-mediated immunodeficiency. Cutaneous granulomas manifestations in children with combined immunodeficiency are rare. Objective: We report the case of a 6-year-old boy who presented with disseminated cutaneous granulomas and a history of multiple infections. Methods and Results: Laboratory evaluation revealed severe combined immunodeficiency, and deoxyribonucleic acid (DNA) analysis confirmed mutations on a gene of chromosome 19 that encodes an enzyme called Janus kinase 3 (Jak-3). Immunohistochemistry revealed expression of CD8 + in the perivascular lymphocytic infiltrate Conclusion: Disseminated granulomatous lesions in children with a history of frequent infections should prompt the clinician to initiate detailed immunocompetence evaluation as they might prove to be the first manifestation of immunologic impairment. Anté cé dents: Les troubles qui pré sentent un dé ficit immunitaire mixte repré sentent un groupe hé té rogè ne de maladies caracté risé es par une immunodé ficience à la fois humorale et à mé diation cellulaire. Les manifestations de granulomes cutané s chez les enfants souffrant d'un dé ficit immunitaire mixte sont rares. Objectif: Rapporter le cas d'un garç on de 6 ans qui pré sentait des granulomes cutané s dissé miné s et un anté cé dent d'infections multiples. Mé thodes et Ré sultats: Les tests de laboratoire ont ré vé lé une immunodé ficience combiné e grave et les analyses de l'ADN ont confirmé les mutations, sur le chromosome 19, du gè ne responsable de l'encodage de l'enzyme Janus kinase 3 (Jak-3). L'immunohistochimie a montré l'expression de CD8 + dans l'infiltrat lymphocytaire pé rivasculaire. Conclusion: Les lé sions granulomateuses dissé miné es chez les enfants pré sentant des anté cé dents d'infections chroniques devront amener le clinicien à entamer une é valuation dé taillé e de l'immunocompé tence, vu que ces lé sions pourraient repré senter la premiè re manifestation d'un dé ficit immunologique.

International Journal of Infectious Diseases, 2012

Background: ‘ALARM’ is a systematic review of available literature aiming to provide updated info... more Background: ‘ALARM’ is a systematic review of available literature aiming to provide updated information on the prevalence of Human Papillomavirus (HPV) in locally-regionally advanced (LA) and recurrent/metastatic (RM) head and neck cancer (HNC) worldwide. Methods: Electronic searches were conducted on clinicaltrials.gov, MEDLINE (via Pubmed), Embase and ASCO/ESMO journals of congresses for interventional studies (IS; phase I-III trials) as well as MEDLINE and Embase for non-interventional studies (NIS) of LA/RM HNC published between 01Jan2010 and 31Dec2020. Criteria for study selection included: availability of HPV prevalence data for patients with LA/RM HNC, patient enrollment from 01Jan2010 onwards, and oropharyngeal cancer (OPC) included among HNC types. HPV prevalence per study was calculated as proportion of HPV-positive (HPV+) over total number of HNC enrolled patients. For overall HPV prevalence across studies, mean of reported HPV prevalence rates across studies and pooled ...

Introduction Rotavirus (RV) infection in neonatal age can be mild or even asymptomatic. Several s... more Introduction Rotavirus (RV) infection in neonatal age can be mild or even asymptomatic. Several studies have reported that RV is responsible for 31%-87% of pediatric nosocomial diarrhea and causes gastroenteritis outbreaks in pediatric and neonatal units. Objectives Study clinical characteristics, genotypes and risk factors of RV infection in neonatal age. Methods A prospective study was conducted from April 2009 till April 2013 in the neonatal special care unit of the largest tertiary pediatric hospital of Greece. Fecal samples and epidemiological data were collected from each neonate with gastrointestinal symptoms. RV antigen was detected with a rapid immunochromatography test. RV positive samples were further genotyped with RT PCR and sequencing using specific VP7 and VP4 primers. Results Positive for RV were 126/415 samples (30.4%). Mean age of onset was 18 days. Seventy four cases (58%) were hospital acquired. Seasonality of RV infection did not differ significantly throughout the year with the exception of 4 outbreaks. Genotypes found during the study period were G4P[8] (58.7%), G1P[8] (14.7%), G12P[8] (9.3%), G3P[8] (9.3%), G12P [6] (5.3%), G9P[8] (1.3%) and G2P[4] (1.3%). RV cases presented with: diarrhea (81%), vomiting (26.2%), fever (34.9%), dehydration (28.6%), feeding intolerance (39.7%), weight loss (54%), whilst 19% of cases were asymptomatic. Comparing community with hospital acquired cases differences in clinical manifestations were found.

Journal of Medical Virology, 2010

HAL is a multidisciplinary open access archive for the deposit and dissemination of scientific re... more HAL is a multidisciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Blood, 2004

Anti-CD20, a chimeric monoclonal antibody (rituximab), binds avidly to the CD20 antigen, which is... more Anti-CD20, a chimeric monoclonal antibody (rituximab), binds avidly to the CD20 antigen, which is expressed almost exclusively on the surface of B-cells in different stages of their development. The observed elimination of B cells from serum and lymphoid tissue of patients treated with anti-CD20 suggests that this agent could have a beneficial effect in immune diseases such as chronic immune thrombocytopenic purpura (cITP), autoimmune hemolytic anemia or hemophilia with inhibitors. Anti-CD20 was given to two children with refractory cITP and another two with hemophilia and FVIII inhibitors. All 4 children had frequent admissions to the hospital and poor quality of life. Anti-CD20 was administered at a dose of 375mg/m2, once weekly, for 4 consecutive weeks. B cells were measured in peripheral blood with monoclonal antibodies CD19 and CD20, before induction of treatment and in certain time-points after drug administration. Case 1: A 5 2/12-year old girl with cITP, diagnosed at the age...

European Journal of Pediatrics, 2007

Cancer Medicine, Jan 20, 2024

Value in Health, Nov 30, 2023

Journal of Postgraduate Medicine, Oct 1, 2004

Ataxia-telangiectasia (A-T) is a rare multisystem, neurodegenerative genetic disorder. We present... more Ataxia-telangiectasia (A-T) is a rare multisystem, neurodegenerative genetic disorder. We present a case of a 6-year-old girl who had a history of frequent respiratory infections and also had ocular and immunological features of this syndrome. The absence of neurological symptoms, which is very unusual for a patient of this age, raised many difficulties in the diagnosis of the disease. It is concluded that a normal neurological assessment must not exclude the diagnosis of AT and delay the proper interventional measures.

Clinical Microbiology and Infection, 2003

We present a case of Guillain-Barré syndrome (GBS) following Campylobacter jejuni HS serotype O:1... more We present a case of Guillain-Barré syndrome (GBS) following Campylobacter jejuni HS serotype O:19 infection in a child. Antibodies against C. jejuni and autoantibodies to the peripheral nerve gangliosides GM1 were positive, a pattern correlating well with the existence of an inflammatory neuropathy like GBS. The patient shared the HLA-B35 and HLA-DR8 antigens, which have been found to be increased in GBS patients with previous C. jejuni infection. As this is the first diagnosed C. jejuni-associated GBS case reported from Greece, further clinical and epidemiologic investigations are warranted.

Haemophilia, 2006

The development of antibodies to factor VIII (FVIII) in severely affected haemophilia A patients ... more The development of antibodies to factor VIII (FVIII) in severely affected haemophilia A patients is a serious complication associated with increased morbidity and mortality. Bypassing agents are used to treat acute bleeding episodes; however, elimination of the inhibitors can only be achieved with immune tolerance therapy (ITT) in 60-80% of cases. High responding (HR) inhibitors are more likely to respond to ITT if the titre is decreased to <5 BU over time or in selected cases after the administration of immunosuppressive drugs, plasmapheresis or immunoabsorption, techniques difficult to apply in children. Anti-CD20 (rituximab), a monoclonal antibody, was given as an alternative treatment in two haemophilic children with HR inhibitors and impaired quality of life, due to recurrent haemarthrosis. Rituximab was given at the dose of 375 mg m)2 , once weekly for four consecutive weeks. Both patients showed a partial response to rituximab reducing the inhibitor titre to <5 BU, thus facilitating ITT initiation; however, only the older patient eradicated the inhibitor within 21 days after application of ITT. The second patient, despite depletion of B cells, did not respond to ITT. No long-term side effects have been observed in both patients for a follow-up period of 20 and 18 months respectively. In conclusion, rituximab appears to be an alternative effective therapy to rapidly reduce or eliminate the inhibitor in selected cases of severely affected haemophiliacs before further proceeding to ITT. However, the dose and appropriate schedule, as well as long-term side effects need further investigation.

Blood, Nov 16, 2005

in the field of palliative medicine, the latter having a significant training requirement in pain... more in the field of palliative medicine, the latter having a significant training requirement in pain management. The report of Hewitt et al tells us about a prospective study that looked at the treatment of pain in children with incurable cancer within the Children's Cancer Study Group centers in the United Kingdom. Although the study did not address the efficacy of the opioid regimens used, it did show that the liberal use of high-potency opiates should be an integral part of interdisciplinary palliative care for advanced cancer. Morphine was the opiate most commonly used and it was often administered intravenously at the end of life. It was clear that some patients required unusually high doses of morphine (more than 20 mg/ kg/24 hours). Some youngsters required as much as 1500 mg/kg/24 hours of morphine to control pain. Obviously, there is a delicate balance between achieving adequate pain control and avoiding undesirable side effects. The provision of sedation to a level that allows a child to be unaware of suffering has also been debated, an area that is ethically challenging. All of us recognize that proper pain management is only a single component of palliative care. As we develop more expertise in palliative care, it may well be that simply administering pain medications will prove not to be the only, or necessarily best, way to alleviate pain. The editorial which accompanied this report reminds us that as many as 80% of the quarter of a million children throughout the world who develop cancer each year die without adequate treatment or without adequate pain relief.

Eurosurveillance, Nov 24, 2022

Haemophilia, 2006

Summary. The development of antibodies to factor VIII (FVIII) in severely affected haemophilia A... more Summary. The development of antibodies to factor VIII (FVIII) in severely affected haemophilia A patients is a serious complication associated with increased morbidity and mortality. Bypassing agents are used to treat acute bleeding episodes; however, elimination of the inhibitors can only be achieved with immune tolerance therapy (ITT) in 60–80% of cases. High responding (HR) inhibitors are more likely to respond to ITT if the titre is decreased to <5 BU over time or in selected cases after the administration of immunosuppressive drugs, plasmapheresis or immunoabsorption, techniques difficult to apply in children. Anti‐CD20 (rituximab), a monoclonal antibody, was given as an alternative treatment in two haemophilic children with HR inhibitors and impaired quality of life, due to recurrent haemarthrosis. Rituximab was given at the dose of 375 mg m−2, once weekly for four consecutive weeks. Both patients showed a partial response to rituximab reducing the inhibitor titre to <5...

Journal of Paediatrics and Child Health, 2003

: A 12‐year‐old girl with chronic otitis media complicated by petrositis and cerebellar abscess ... more : A 12‐year‐old girl with chronic otitis media complicated by petrositis and cerebellar abscess is presented. Early surgical intervention, in combination with broad‐spectrum antibiotics, provided a good outcome. Life‐threatening complications of otitis media, although rare, still occur in developed countries.

Purpose: To investigate the presence of early indicators of the dysmetabolic syndrome (DS) in a p... more Purpose: To investigate the presence of early indicators of the dysmetabolic syndrome (DS) in a population of young survivors with acute lymphoblastic leukemia (ALL) in childhood. Patients and Methods: We enrolled randomly 80 patients with ALL (50 males) diagnosed between 1991-2002. The median age at the time of study entry was 13.9 yrs (range, 5.2-24.1) and the median interval since completion of chemotherapy was 6.3 yrs (range, 1.1-12.2). Sixty-two patients (Group A) received chemotherapy only, while 18 patients (Group B) received chemotherapy and cranial irradiation (18 Gy). The investigation included epidemiological, clinical, biochemical, hormonological and imaging data in order to detect early indicators of DS development. Results: An unhealthy diet (74%; CI 95%, 63.1-82.2%) and absence of regular physical activity (64%; CI 95%, 52.8-73.4%) were reported, while frank obesity (25%; CI 95%, 16.7-35.6%), increased blood pressure (21%; CI 95%, 13.6-31.5%), increased serum triglyce...

Blood, 2009

4112 New treatment protocols have improved significantly the survival of patients with acute lymp... more 4112 New treatment protocols have improved significantly the survival of patients with acute lymphocytic leukemia (ALL). However, there is a risk of relapse, which depends on disease classification and the protocol of chemotherapy administered. In case of relapse, new remission has to be achieved to proceed to bone marrow transplantation (BMT). For this reason, new therapies for remission induction, except standard chemotherapy, are under investigation. Clofarabine, a new class agent, is a nucleoside analogue of purine which inhibits DNA synthesis and repair by blocking ribonucleoside reductase and DNA polymerase. It also disrupts mitochondrial membrane, driving to cell apoptosis. We describe two children with B-cell ALL, in whom clofarabine was administered because of disease resistance. Case 1: Girl, 12 years old, with ALL, presented a second bone marrow (BM) relapse. The first relapse was also in BM and was presented 30 months after the end of primary chemotherapy. Remission was ...

Background: Combined immunodeficiency disorders comprise a heterogeneous group of diseases charac... more Background: Combined immunodeficiency disorders comprise a heterogeneous group of diseases characterized by both humoral and cell-mediated immunodeficiency. Cutaneous granulomas manifestations in children with combined immunodeficiency are rare. Objective: We report the case of a 6-year-old boy who presented with disseminated cutaneous granulomas and a history of multiple infections. Methods and Results: Laboratory evaluation revealed severe combined immunodeficiency, and deoxyribonucleic acid (DNA) analysis confirmed mutations on a gene of chromosome 19 that encodes an enzyme called Janus kinase 3 (Jak-3). Immunohistochemistry revealed expression of CD8 + in the perivascular lymphocytic infiltrate Conclusion: Disseminated granulomatous lesions in children with a history of frequent infections should prompt the clinician to initiate detailed immunocompetence evaluation as they might prove to be the first manifestation of immunologic impairment. Anté cé dents: Les troubles qui pré sentent un dé ficit immunitaire mixte repré sentent un groupe hé té rogè ne de maladies caracté risé es par une immunodé ficience à la fois humorale et à mé diation cellulaire. Les manifestations de granulomes cutané s chez les enfants souffrant d'un dé ficit immunitaire mixte sont rares. Objectif: Rapporter le cas d'un garç on de 6 ans qui pré sentait des granulomes cutané s dissé miné s et un anté cé dent d'infections multiples. Mé thodes et Ré sultats: Les tests de laboratoire ont ré vé lé une immunodé ficience combiné e grave et les analyses de l'ADN ont confirmé les mutations, sur le chromosome 19, du gè ne responsable de l'encodage de l'enzyme Janus kinase 3 (Jak-3). L'immunohistochimie a montré l'expression de CD8 + dans l'infiltrat lymphocytaire pé rivasculaire. Conclusion: Les lé sions granulomateuses dissé miné es chez les enfants pré sentant des anté cé dents d'infections chroniques devront amener le clinicien à entamer une é valuation dé taillé e de l'immunocompé tence, vu que ces lé sions pourraient repré senter la premiè re manifestation d'un dé ficit immunologique.

International Journal of Infectious Diseases, 2012

Background: ‘ALARM’ is a systematic review of available literature aiming to provide updated info... more Background: ‘ALARM’ is a systematic review of available literature aiming to provide updated information on the prevalence of Human Papillomavirus (HPV) in locally-regionally advanced (LA) and recurrent/metastatic (RM) head and neck cancer (HNC) worldwide. Methods: Electronic searches were conducted on clinicaltrials.gov, MEDLINE (via Pubmed), Embase and ASCO/ESMO journals of congresses for interventional studies (IS; phase I-III trials) as well as MEDLINE and Embase for non-interventional studies (NIS) of LA/RM HNC published between 01Jan2010 and 31Dec2020. Criteria for study selection included: availability of HPV prevalence data for patients with LA/RM HNC, patient enrollment from 01Jan2010 onwards, and oropharyngeal cancer (OPC) included among HNC types. HPV prevalence per study was calculated as proportion of HPV-positive (HPV+) over total number of HNC enrolled patients. For overall HPV prevalence across studies, mean of reported HPV prevalence rates across studies and pooled ...

Introduction Rotavirus (RV) infection in neonatal age can be mild or even asymptomatic. Several s... more Introduction Rotavirus (RV) infection in neonatal age can be mild or even asymptomatic. Several studies have reported that RV is responsible for 31%-87% of pediatric nosocomial diarrhea and causes gastroenteritis outbreaks in pediatric and neonatal units. Objectives Study clinical characteristics, genotypes and risk factors of RV infection in neonatal age. Methods A prospective study was conducted from April 2009 till April 2013 in the neonatal special care unit of the largest tertiary pediatric hospital of Greece. Fecal samples and epidemiological data were collected from each neonate with gastrointestinal symptoms. RV antigen was detected with a rapid immunochromatography test. RV positive samples were further genotyped with RT PCR and sequencing using specific VP7 and VP4 primers. Results Positive for RV were 126/415 samples (30.4%). Mean age of onset was 18 days. Seventy four cases (58%) were hospital acquired. Seasonality of RV infection did not differ significantly throughout the year with the exception of 4 outbreaks. Genotypes found during the study period were G4P[8] (58.7%), G1P[8] (14.7%), G12P[8] (9.3%), G3P[8] (9.3%), G12P [6] (5.3%), G9P[8] (1.3%) and G2P[4] (1.3%). RV cases presented with: diarrhea (81%), vomiting (26.2%), fever (34.9%), dehydration (28.6%), feeding intolerance (39.7%), weight loss (54%), whilst 19% of cases were asymptomatic. Comparing community with hospital acquired cases differences in clinical manifestations were found.

Journal of Medical Virology, 2010

HAL is a multidisciplinary open access archive for the deposit and dissemination of scientific re... more HAL is a multidisciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Blood, 2004

Anti-CD20, a chimeric monoclonal antibody (rituximab), binds avidly to the CD20 antigen, which is... more Anti-CD20, a chimeric monoclonal antibody (rituximab), binds avidly to the CD20 antigen, which is expressed almost exclusively on the surface of B-cells in different stages of their development. The observed elimination of B cells from serum and lymphoid tissue of patients treated with anti-CD20 suggests that this agent could have a beneficial effect in immune diseases such as chronic immune thrombocytopenic purpura (cITP), autoimmune hemolytic anemia or hemophilia with inhibitors. Anti-CD20 was given to two children with refractory cITP and another two with hemophilia and FVIII inhibitors. All 4 children had frequent admissions to the hospital and poor quality of life. Anti-CD20 was administered at a dose of 375mg/m2, once weekly, for 4 consecutive weeks. B cells were measured in peripheral blood with monoclonal antibodies CD19 and CD20, before induction of treatment and in certain time-points after drug administration. Case 1: A 5 2/12-year old girl with cITP, diagnosed at the age...

European Journal of Pediatrics, 2007